Hematologic Oncology Update Chronic Lymphocytic Leukemia — Year in Review Series on Relevant New Datasets and Advances
May 3, 2025
Dr. Jennifer R Brown, a leader in CLL research at Dana-Farber, and Prof. Paolo Ghia from Milan, dive into the latest breakthroughs in chronic lymphocytic leukemia. They explore the role of new therapies like BTK inhibitors, comparing their effectiveness with traditional treatments. The conversation highlights the significance of monitoring minimal residual disease and discusses recent findings on treatment risks like hypertension. They also touch on innovative strategies emerged during the COVID-19 pandemic, paving the way for future advancements in CLL care.
AI Snips
Chapters
Transcript
Episode notes
Novel Therapies Improve CLL Outcomes
- Novel therapies have improved both survival and quality of life in CLL patients with aggressive disease.
- Transformation rates appear lower with longer and more effective treatments.
BTK Inhibitors Normalize Life Expectancy
- Life expectancy in CLL patients treated with BTK inhibitors now parallels that of healthy individuals.
- This progress allows focus to shift toward achieving a definitive cure.
Use MRD to Guide Time-Limited Therapy
- Adopt time-limited combination therapies to achieve deeper remissions and allow treatment breaks.
- Use MRD-guided approaches selectively to optimize treatment duration in trials and practice.